-
12/17/2017
PAION grants exclusive license to Mundipharma for development and commercialization of remimazolam in Japan
-
11/14/2017
FDA considers current human abuse liability program with Remimazolam in the U.S. as sufficient; no second intranasal study required
-
07/17/2017
PAION AG raises EUR 8.0 million in private placement
-
06/28/2017
PAION reports positive headline data in U.S. Phase III trial with remimazolam for procedural sedation during bronchoscopy
-
03/27/2017
PAION successfully completes patient recruitment in U.S. Phase III study with remimazolam for procedural sedation during bronchoscopy
-
03/26/2017
PAION reports positive headline data in U.S. clinical safety trial of remimazolam in high-risk patients undergoing colonoscopy
-
02/07/2017
PAION AG to issue approx 2.4 Million Shares at EUR 2.05 per share in capital increase with subscription rights